Product Images Losartan Potassium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Losartan Potassium NDC 68071-5184 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

PDP - 68071 5184 3

PDP - 68071 5184 3

NuCare Pharmaceuticals, Inc. offers Losartan Potassium tablets in 50mg strength. Each tablet is round, green, and scored with "a" and "54 125" debossed on either side. The tablets come in a bottle of 30 with an expiry date of 00-00 and lot number 000000. The tablets contain the active ingredient Losartan along with other inactive ones. NuCare Pharmaceuticals, Inc. warns individuals to keep this medication out of reach of children and store it at 68-77°F. If you experience side effects, contact your doctor or call FDA at 1-800-FDA-1088.*

chem.jpg - chem

chem.jpg - chem

fig1.jpg - fig1

fig1.jpg - fig1

This is a comparison between the drugs Atenolol and Losartan. The data shows the percentage of patients with the primary endpoint, along with an adjusted risk reduction of 13% with a p-value of 0.021. The study was conducted over 66 months, with monthly observations at various intervals.*

fig2.jpg - fig2

fig2.jpg - fig2

This text represents a graph or a chart suggesting a comparison between Atenolol and Losartan in terms of their efficacy in reducing fatal and non-fatal strokes among patients. The x-axis represents the study month, and the y-axis represents the percentage of patients who experienced fatal/non-fatal strokes. No further information is available.*

fig3.jpg - fig3

fig3.jpg - fig3

This text appears to be a comparison of the stroke rates among patients who were given Losartan and Atenolol drugs. The table shows the number of events, hazard ratios, and rates of the primary composite stroke (fatal/non-fatal) based on the patients' age, gender, race, and history of CVD. The results suggest that Losartan may be more effective than Atenolol in some cases.*

fig4.jpg - fig4

fig4.jpg - fig4

This appears to be a graph or chart displaying the results of a study involving Losartan and a placebo, showing a 16.1% reduction in risk. The graph could be displaying time on the x-axis and some form of measurement on the y-axis, but without more information, a more specific description is not available.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.